Loading…
TOXICOLOGICAL STUDIES ON A NEW MACROLIDE ANTIBIOTIC, MIDECAMYCIN ACETATE (MIOCAMYCIN): PART IV-12. TOXICITY OF METABOLITES OF MIOCAMYCIN: SUBACUTE TOXICITY OF Mb12 IN RATS
Miocamycin (MOM) is a derivative of midecamycin, a macrolide antibiotic isolated from a culture broth of Streptomyces mycarofaciens1, 2). It is reported that MOM has the most interesting antibacterial properties among macrolide antibiotics3, 4) and is metabolized into 4 main metabolites of Mb1, Mb2,...
Saved in:
Published in: | Japanese journal of antibiotics 1984/08/25, Vol.37(8), pp.1552-1564 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Miocamycin (MOM) is a derivative of midecamycin, a macrolide antibiotic isolated from a culture broth of Streptomyces mycarofaciens1, 2). It is reported that MOM has the most interesting antibacterial properties among macrolide antibiotics3, 4) and is metabolized into 4 main metabolites of Mb1, Mb2, Mb6, and Mb125). It is also known that LD0 values of Mb12 were estimated more than 5,000mg/kg without exhibiting any manifest toxic effects after single oral administration to male and female rats6). The object of this study was to examine toxicological effects in male and female rats after repeated oral administration of Mb12, a metabolite of MOM, for 5 weeks at a daily dosage of 125, 250, 500 and 1,000mg/kg which were selected in consideration of the maximum tolerable dosage level of 1,000mg/kg/day in MOM rat subacute toxicity studies as previously reported7). |
---|---|
ISSN: | 0368-2781 2186-5477 |
DOI: | 10.11553/antibiotics1968b.37.1552 |